PARK8 LRRK2 parkinsonism

Kristoffer Haugarvoll, Zbigniew K Wszolek

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Parkinson's disease (PD) is the most common form of parkinsonism, affecting nearly 2% of people older than 65 years of age. Symptomatic treatment has been available for decades, but to date there is no treatment retarding disease progression. Over the past decade several genes causing parkinsonism have been identified in families with a mendelian pattern of inheritance. The most recent is the leucine-rich repeat kinase 2 (LRRK2) gene. Pathogenic mutations in the LRRK2 gene cause a significant proportion of clinically typical, late-onset PD. This review summarizes the current knowledge on the contribution of LRRK2 mutations in understanding parkinsonism.

Original languageEnglish (US)
Pages (from-to)287-294
Number of pages8
JournalCurrent Neurology and Neuroscience Reports
Volume6
Issue number4
DOIs
StatePublished - Jul 2006

Fingerprint

Parkinsonian Disorders
Leucine
Phosphotransferases
Parkinson Disease
Genes
Inheritance Patterns
Mutation
Disease Progression

ASJC Scopus subject areas

  • Medicine(all)
  • Neuroscience(all)

Cite this

PARK8 LRRK2 parkinsonism. / Haugarvoll, Kristoffer; Wszolek, Zbigniew K.

In: Current Neurology and Neuroscience Reports, Vol. 6, No. 4, 07.2006, p. 287-294.

Research output: Contribution to journalArticle

Haugarvoll, Kristoffer ; Wszolek, Zbigniew K. / PARK8 LRRK2 parkinsonism. In: Current Neurology and Neuroscience Reports. 2006 ; Vol. 6, No. 4. pp. 287-294.
@article{044c20e91eb74913a5cb6b6909b61b63,
title = "PARK8 LRRK2 parkinsonism",
abstract = "Parkinson's disease (PD) is the most common form of parkinsonism, affecting nearly 2{\%} of people older than 65 years of age. Symptomatic treatment has been available for decades, but to date there is no treatment retarding disease progression. Over the past decade several genes causing parkinsonism have been identified in families with a mendelian pattern of inheritance. The most recent is the leucine-rich repeat kinase 2 (LRRK2) gene. Pathogenic mutations in the LRRK2 gene cause a significant proportion of clinically typical, late-onset PD. This review summarizes the current knowledge on the contribution of LRRK2 mutations in understanding parkinsonism.",
author = "Kristoffer Haugarvoll and Wszolek, {Zbigniew K}",
year = "2006",
month = "7",
doi = "10.1007/s11910-006-0020-0",
language = "English (US)",
volume = "6",
pages = "287--294",
journal = "Current Neurology and Neuroscience Reports",
issn = "1528-4042",
publisher = "Current Medicine Group",
number = "4",

}

TY - JOUR

T1 - PARK8 LRRK2 parkinsonism

AU - Haugarvoll, Kristoffer

AU - Wszolek, Zbigniew K

PY - 2006/7

Y1 - 2006/7

N2 - Parkinson's disease (PD) is the most common form of parkinsonism, affecting nearly 2% of people older than 65 years of age. Symptomatic treatment has been available for decades, but to date there is no treatment retarding disease progression. Over the past decade several genes causing parkinsonism have been identified in families with a mendelian pattern of inheritance. The most recent is the leucine-rich repeat kinase 2 (LRRK2) gene. Pathogenic mutations in the LRRK2 gene cause a significant proportion of clinically typical, late-onset PD. This review summarizes the current knowledge on the contribution of LRRK2 mutations in understanding parkinsonism.

AB - Parkinson's disease (PD) is the most common form of parkinsonism, affecting nearly 2% of people older than 65 years of age. Symptomatic treatment has been available for decades, but to date there is no treatment retarding disease progression. Over the past decade several genes causing parkinsonism have been identified in families with a mendelian pattern of inheritance. The most recent is the leucine-rich repeat kinase 2 (LRRK2) gene. Pathogenic mutations in the LRRK2 gene cause a significant proportion of clinically typical, late-onset PD. This review summarizes the current knowledge on the contribution of LRRK2 mutations in understanding parkinsonism.

UR - http://www.scopus.com/inward/record.url?scp=33746122667&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746122667&partnerID=8YFLogxK

U2 - 10.1007/s11910-006-0020-0

DO - 10.1007/s11910-006-0020-0

M3 - Article

C2 - 16822348

AN - SCOPUS:33746122667

VL - 6

SP - 287

EP - 294

JO - Current Neurology and Neuroscience Reports

JF - Current Neurology and Neuroscience Reports

SN - 1528-4042

IS - 4

ER -